UniQure Has High HOPE For Hemophilia B Gene Therapy

The Dutch company's update on AMT-061 and the initiation of a pivotal trial called HOPE-B of around 50 patients could put the product in pole position to be the first gene therapy on the market for the severe orphan blood clotting disorder.

Racing cars
Uniqure in pole position for hemophilia gene therapy? • Source: Shutterstock

uniQure NV has presented promising updated results from a Phase IIb trial of its gene therapy AMT-061 for hemophilia B which the Netherlands-headquartered firm believes could be best in class and first to market ahead of Spark Therapeutics Inc. and Pfizer Inc.'s rival candidate.

Initial data released in November demonstrated that after six weeks, three patients receiving AMT-061, an AAV5-based gene therapy which contains...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Blood and Clotting

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone

 

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod

 

US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.

Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III

 

The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.

Abecma Or Bust: 2seventy Sells Final Research Program To Novo

 

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.